Elizabeth A. Mittendorf, MD, PhD, and Lisa A. Carey, MD, on Chemoendocrine Treatment in Breast Cancer: the TAILORx Trial

Posted: Monday, June 11, 2018

Elizabeth A. Mittendorf, MD, PhD, of Dana-Farber/Brigham and Women’s Cancer Center, and Lisa A. Carey, MD, of the University of North Carolina, discuss the impact of new phase III findings on chemoendocrine treatment vs endocrine treatment alone in hormone receptor–positive, HER2-negative, node-negative breast cancer.